Myeloma Minute: Be a #myelomawarrior
|
| ACTION | Be a Myeloma Warrior
Kick Off Myeloma Action Month with Us Tomorrow, March 1stThis year’s Myeloma Action Month (MAM), beginning March 1, 2019, focuses on Myeloma Warriors. The IMF is asking individuals like YOU to spread multiple myeloma awareness on a global scale. Here’s how:
We cannot wait to see all the ways in which you TAKE ACTION to increase myeloma awareness!
|
|
|
| INNOVATION | Latest Research
Subcutaneous Daratumumab Meets Primary Endpoints in StudyOn February 25, 2019, Genmab A/S, the developer and manufacturer of Darzalex (daratumumab), announced topline results of the phase III COLUMBA study of subcutaneous (SC) daratumumab versus intravenous (IV) daratumumab for patients with relapsed or refractory myeloma. According to AP News, “the results showed that SC administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 is non-inferior to IV administration of daratumumab with regard to the co-primary end points of overall response rate (ORR) and Maximum Trough concentration (Ctrough) of daratumumab on day 1 of the third treatment cycle.” Not only was the safety profile similar, but patients who had SC daratumumab actually had slightly improved response rates compared to those who received it by intravenous infusion.
|
|
|
| EDUCATION | Workshop
|
| ACTION | Award Applications
|
Register Now for a Regional Community Workshop in La Jolla, California |
Attention Myeloma Researchers! Funding Opportunity |
|
The IMF will host a Regional Community Workshop at the San Diego Marriot (4240 La Jolla Village Dr.) in La Jolla, CA, on Saturday, March 23, 2019. Registration is FREE, but seating is limited. Learn from and meet one-on-one with myeloma experts Caitlin Costello, MD (UCSD/Sharp Healthcare Transplant Program, San Diego, CA), David H. Vesole, MD, PhD (John Theurer Cancer Center, Hackensack, NJ), and Deborah Doss RN, OCN (Dana-Farber Cancer Institute, Boston, MA). |
The Department of Defense’s Peer Reviewed Cancer Research Program has released pre-announcements for researchers to have ample time to prepare their applications for funding. Myeloma researchers are eligible for this funding due to IMF’s advocacy on Capitol Hill to ensure blood cancers would remain as a topic area under the program for FY 2019. Review the pre-announcement at the link below. You can also reach out to advocacy@myeloma.org if you have any questions. |
|
|
|
|
| INSPIRATION | Fundraiser
Register Now for Myeloma Miracles 2019 Walk in Southern CaliforniaTwo Southern California support groups — the Inland Empire and Inland Valley Warriors — are walking to raise money for the International Myeloma Foundation’s research and education initiatives. If you are in the area, join the First Annual Walk for Myeloma Miracles fundraiser at Central Park (11200 Base Line Rd), in Rancho Cucamonga, California, on March 9, 2019, at 9 a.m. PST. Sign up as an individual or as a team.
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study Join the conversation about myeloma on the Smart Patients Message Board |
March 15-16, 2019 March 23, 2019 April 5-6, 2019 April 6, 2019 April 27, 2019 May 11, 2019 |
Amgen, Celgene Corporation, Genentech, Sanofi-Genzyme, and Takeda Oncology
and individuals like you who supported the IMF this year